Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Pharmaceutical TechnologyNew data presented at ACC 2026 clarifies sotatercept's role alongside vasodilator-based regimens in PAH patients.Clinical DataCardiovascularRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients. Clinical DataCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is ChillingNext: Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
